The oesophagus as an immune organ
10.1038/s41575-025-01086-4 · doi-reference
Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice
10.1126/science.adp0240 · doi-reference
Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to ingested antigens
10.1126/science.adp0246 · doi-reference
Neuropsychiatric reactions with the use of montelukast
10.1136/bmj-2021-067554 · doi-reference
Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review
10.1186/s12876-021-01854-x · doi-reference
Proton pump inhibitor treatment decreased duodenal and esophageal eosinophilia in a case of eosinophilic gastroenteritis
10.1016/j.alit.2015.06.002 · doi-reference
Eosinophilic gastroenteritis as a cause of gastrointestinal tract bleeding and protein-losing enteropathy
10.14744/turkpediatriars.2018.48376 · doi-reference
10.1016/j.jaci.2020.09.039
10.1016/j.jaci.2020.09.039 · doi-reference
10.1186/1476-7961-9-7
10.1186/1476-7961-9-7 · doi-reference
10.1016/j.jaci.2007.06.015
10.1016/j.jaci.2007.06.015 · doi-reference
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial
10.1016/s2468-1253(26)00116-0 · doi-reference
Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
10.3390/biom13010112 · doi-reference
A Case Series on the Use of Dupilumab for Treatment of Refractory Eosinophilic Gastrointestinal Disorders
10.1097/mpg.0000000000003512 · doi-reference
Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series
10.14309/ctg.0000000000000646 · doi-reference
Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report
10.5217/ir.2024.00013 · doi-reference
Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis
10.1016/j.cgh.2018.03.024 · doi-reference
10.17235/reed.2024.10660/2024
10.17235/reed.2024.10660/2024 · doi-reference
Successful Treatment of Steroid-resistant Eosinophilic Gastrointestinal Disease with Mepolizumab
10.2169/internalmedicine.0801-22 · doi-reference
Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab
10.1016/j.anai.2018.07.030 · doi-reference
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
10.1186/s13223-020-00423-3 · doi-reference
10.1016/j.jaci.2004.08.027
10.1016/j.jaci.2004.08.027 · doi-reference
Pilot study of anti-IL-5 in eosinophilic gastroenteritis
10.1016/s0091-6749(03)80986-7 · doi-reference
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial
10.1016/s2468-1253(23)00145-0 · doi-reference
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
10.1056/nejmoa1812185 · doi-reference
10.1056/nejmoa2012047
10.1056/nejmoa2012047 · doi-reference
Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis
10.1016/j.alit.2022.11.001 · doi-reference
Clinical, histopathological features and efficacy of elimination diet and proton-pump inhibitor therapy in achieving histological remission in Asian children with eosinophilic gastritis
10.1111/jpc.15969 · doi-reference
Elemental diet therapy for eosinophilic gastroenteritis and dietary habits
10.1111/ped.14894 · doi-reference
Efficacy of Dietary Treatment for Inducing Disease Remission in Eosinophilic Gastroenteritis
10.1097/mpg.0000000000000766 · doi-reference
10.1038/ajg.2014.166
10.1038/ajg.2014.166 · doi-reference
Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experience
10.1016/j.jaip.2019.01.053 · doi-reference
Retrospective study of budesonide in children with eosinophilic gastroenteritis
10.1038/s41390-019-0444-2 · doi-reference
Biologics in eosinophilic gastrointestinal diseases
10.1016/j.anai.2022.06.015 · doi-reference
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
10.1007/s12325-022-02202-5 · doi-reference
Correlation between anxiety and decreased quality of life in patients with non-esophageal eosinophilic gastrointestinal diseases
10.1002/jgh3.13025 · doi-reference
Psychiatric Comorbidities Are Highly Prevalent in Nonesophageal Eosinophilic Gastrointestinal Diseases
10.1016/j.cgh.2021.05.044 · doi-reference
10.1016/j.jpeds.2009.11.008
10.1016/j.jpeds.2009.11.008 · doi-reference
High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases
10.1097/mpg.0000000000002817 · doi-reference
Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care
10.1016/j.clinre.2018.03.003 · doi-reference
Initial Validation of the Eosinophilic Gastritis and Gastroenteritis Quality of Life Scale
10.1016/j.gastha.2025.100627 · doi-reference
